ArticleCancer microenvironment : official journal of the International Cancer Microenvironment Society2015
Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy.
Article in Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Lipid metabolism associated with efficacy of metronomic capecitabine and camrelizumab in gastrointestinal cancer: an exploratory clinical trial.BMC medicine · 2025Trial
- Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial.Breast cancer research : BCR · 2019Trial
- CMTM6/PD-L1-targeted AAV promotes anti-tumor immune responses and chemotherapy responsiveness.Frontiers in immunology · 2026Article
- In Situ Cancer Vaccines: Redefining Immune Activation in the Tumor Microenvironment.ACS biomaterials science & engineering · 2025Review
- Serum Onconeural Antibodies in Dogs and Cats for Early Diagnosis of Cancer.Veterinary medicine (Auckland, N.Z.) · 2025Article
- Article
- The modulation of local and systemic anti-tumor immune response induced by methotrexate nanoconjugate in murine MC38 colon carcinoma and B16 F0 melanoma tumor models.American journal of cancer research · 2023Article
- Treatment and Survival Outcomes Associated With Platinum Plus Low-Dose, Long-term Fluorouracil for Metastatic Nasopharyngeal Carcinoma.JAMA network open · 2021Article
- Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells.Communications biology · 2021Article
- Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study.Journal for immunotherapy of cancer · 2020Article
- Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines.Cancer letters · 2019Review
- Targeting myeloid regulators by paclitaxel-loaded enzymatically degradable nanocups.Nanoscale · 2018Article
- The failure of radical treatments to cure cancer: can less deliver more?Therapeutic advances in vaccines and immunotherapy · 2018Review
- Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice.Oncotarget · 2017Article
- Vitamin E-rich Nanoemulsion Enhances the Antitumor Efficacy of Low-Dose Paclitaxel by Driving Th1 Immune Response.Pharmaceutical research · 2017Article
- Metronomics: towards personalized chemotherapy?Nature reviews. Clinical oncology · 2014Review
- Nanocarrier-based immunotherapy in cancer management and research.ImmunoTargets and therapy · 2014Review
- Prodrugs of paclitaxel improve in situ photo-vaccination.Photochemistry and photobiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Traditionally, anticancer chemotherapy has been generally considered to be strongly immunosuppressive. However, increasing evidence suggests that certain chemotherapeutic agents rely on the induction of antitumor immune responses, in both experimental animal models and patients with cancer. Many of these chemotherapeutic agents exert immunogenic effects via the induction and release of immunostimulatory "danger" signals from dying cancerous cells when used in low doses. New data suggests that several common chemotherapeutic agents may also display direct stimulating effects on immune cells even when applied in ultra-low concentrations (chemoimmunomodulation). Importantly, it is becoming clear that both immune effector cells and immune regulatory cells can be targeted by various chemotherapeutic agents to produce favorable antitumor immune responses. Therefore, utilizing cancer drugs to enhance host antitumor immunity should be considered a feasible therapeutic approach; and recent characterization of the immunomodulatory mechanisms of anticancer chemotherapy using both new and traditional cytotoxic agents suggests that combinations of these approaches with "classical" immunomodulatory agents could lead to a viable new therapeutic paradigm for the treatment of cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.